Somatic mutations in chromatin remodeler genes could modify the epigenomic landscape of CLL, but They may be uncommon in this malignancy compared to other lymphoid neoplasms. CHD2Duvelisib was the 2nd PI3K inhibitor authorised by the FDA, also according to a phase III randomized trial.130 The efficacy and safety profile of the drug appear comparabl… Read More